Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Notizie Vai al feed delle notizie

Oriola Q1 2026: product segment drives growth, services and Kronans Apotek weigh on results

Oriola reports Q1 2026 revenue up 10.7% (excluding the divested Swedish dose-dispensing business) and a slightly higher adjusted EBITDA of €7.7m. The product segment grew 10% to €15.4m and raised its adjusted EBITDA margin to 13.9%, while the services segment faced margin pressure despite revenue growth. Burdens included losses from the joint venture Kronans Apotek (at-equity effect of €2.3m) and increased investments in ERP and automation; free cash flow turned to -€20.9m. Oriola confirms its 2026 outlook, targeting a higher adjusted EBITDA versus 2025 and focusing on operational efficiency and medium-term transformation measures. » Altro su de.investing.com
Oriola posts strong sales growth in 2025, weighed down by high transformation costs

Oriola increased net sales in 2025 by 14% to EUR 1,906 million and improved its trading margin and adjusted EBITDA to EUR 35.1 million, but recorded a net loss of EUR 27.2 million. Major burdens were ERP implementation costs of EUR 9.6 million, impairments of EUR 5.7 million and losses from the Kronans Apotek joint venture of EUR 22.8 million. Free cash flow and the balance sheet improved markedly (free cash flow EUR 58.4 million; net cash EUR 82.1 million) and the company plans a highly automated distribution centre in Järvenpää (EUR 110–120 million). For 2026 Oriola expects rising adjusted EBITDA; the board proposes a dividend of EUR 0.03 per share. » Altro su de.investing.com

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2026, Oriola Corp Class B ha già distribuito 0,03€ di dividendi. L'ultimo pagamento è avvenuto a aprile.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Oriola Corp Class B ha registrato ricavi pari a 51,80M€ e un utile netto di −1,30M€

(EUR)	giu 2026	YoY
Ricavi	+51,80M	89,84%
Utile lordo	+400,00k	97,22%
Utile netto	−1,30M	76,79%
EBITDA	+3,80M	137,50%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+165,96M€
Numero di azioni	181,38M
Massimo/minimo a 52 settimane	+1,53€ - +0,89€
Rendimento da dividendo	+3,30%
Dividendi TTM	+0,03€
Beta	0,48
Rapporto P/E	−8,55
Rapporto PEG	−0,19
Rapporto P/B	+1,90
Rapporto P/S	+0,16

Profilo aziendale

Oriola Oyj bietet Gesundheits- und Wellnessprodukte in Schweden, Finnland und international an. Das Unternehmen bietet rezeptfreie Arzneimittel und Handelswaren, Vitamine, Nahrungsergänzungsmittel, Kosmetika, Hautpflegeprodukte, Sportgetränke und Wundpflegeprodukte an. Darüber hinaus bietet es Logistik-, Beratungs-, Vertriebs- und Marketing- sowie Expertendienstleistungen für Pharmaunternehmen, Apotheken, Krankenhausapotheken, Tierärzte und den Lebensmittelhandel an. Darüber hinaus bietet das Unternehmen pharmazeutische Personal- und Dosierungsdienstleistungen für öffentliche und private Gesundheitsdienstleister, Apotheken, Lebensmittelgeschäfte, Tierärzte und Einzelhändler an. Zum 31. Dezember 2021 betrieb das Unternehmen 319 Apotheken in Schweden und betreibt auch Online-Apotheken. Das Unternehmen war früher als Oriola-KD Oyj bekannt und änderte im April 2017 seinen Namen in Oriola Oyj. Der Hauptsitz von Oriola Oyj befindet sich in Espoo, Finnland.